A Novel Prodrug Strategy Based on Reversibly Degradable Guanidine Imides for High Oral Bioavailability and Prolonged Pharmacokinetics of Broad-Spectrum Anti-influenza Agents
Yujeong Jung, Soo Bin Ahn, Taeyang An*, Hyeon-Min Cha, Minjae Kim, Hyunjin Cheon, Yejin Jang, Haemi Lee, Byungil Kim, Meehyein Kim* and Yan Lee*,
{"title":"A Novel Prodrug Strategy Based on Reversibly Degradable Guanidine Imides for High Oral Bioavailability and Prolonged Pharmacokinetics of Broad-Spectrum Anti-influenza Agents","authors":"Yujeong Jung, Soo Bin Ahn, Taeyang An*, Hyeon-Min Cha, Minjae Kim, Hyunjin Cheon, Yejin Jang, Haemi Lee, Byungil Kim, Meehyein Kim* and Yan Lee*, ","doi":"10.1021/acscentsci.4c0054810.1021/acscentsci.4c00548","DOIUrl":null,"url":null,"abstract":"<p >We present orally administrable prodrugs (<b>OSC-GCDI</b>s) of guanidino oseltamivir carboxylate (<b>GOC</b>) based on guanidine cyclic diimide (GCDI) to treat influenza viruses. By concealing the guanidine group, which significantly limits the intestinal absorption, its prodrugs <b>OSC-GCDI</b>s demonstrate dramatic improvement of oral bioavailability. The most promising antiviral substance <b>OSC-GCDI(P)</b> readily forms covalent adducts with serum proteins via a degradable linker after the intestinal absorption. Subsequently, the active species, <b>GOC</b>, is released from the conjugate in a sustained manner, which greatly contributes to improving pharmacokinetic properties. Because of the remarkable improvements in both oral bioavailability and longevity of its active metabolite, <b>OSC-GCDI(P)</b> demonstrates outstanding therapeutic efficacy against both wild-type and oseltamivir-resistant (H275Y) influenza virus strains in a mouse infection model, even with a single oral administration.</p><p >Guanidine cyclic diimide-based prodrugs dramatically enhance oral bioavailability and pharmacokinetic half-life to show long-time therapeutic activity against broad-spectrum influenza viruses.</p>","PeriodicalId":10,"journal":{"name":"ACS Central Science","volume":null,"pages":null},"PeriodicalIF":12.7000,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.acs.org/doi/epdf/10.1021/acscentsci.4c00548","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Central Science","FirstCategoryId":"92","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acscentsci.4c00548","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0
Abstract
We present orally administrable prodrugs (OSC-GCDIs) of guanidino oseltamivir carboxylate (GOC) based on guanidine cyclic diimide (GCDI) to treat influenza viruses. By concealing the guanidine group, which significantly limits the intestinal absorption, its prodrugs OSC-GCDIs demonstrate dramatic improvement of oral bioavailability. The most promising antiviral substance OSC-GCDI(P) readily forms covalent adducts with serum proteins via a degradable linker after the intestinal absorption. Subsequently, the active species, GOC, is released from the conjugate in a sustained manner, which greatly contributes to improving pharmacokinetic properties. Because of the remarkable improvements in both oral bioavailability and longevity of its active metabolite, OSC-GCDI(P) demonstrates outstanding therapeutic efficacy against both wild-type and oseltamivir-resistant (H275Y) influenza virus strains in a mouse infection model, even with a single oral administration.
Guanidine cyclic diimide-based prodrugs dramatically enhance oral bioavailability and pharmacokinetic half-life to show long-time therapeutic activity against broad-spectrum influenza viruses.
期刊介绍:
ACS Central Science publishes significant primary reports on research in chemistry and allied fields where chemical approaches are pivotal. As the first fully open-access journal by the American Chemical Society, it covers compelling and important contributions to the broad chemistry and scientific community. "Central science," a term popularized nearly 40 years ago, emphasizes chemistry's central role in connecting physical and life sciences, and fundamental sciences with applied disciplines like medicine and engineering. The journal focuses on exceptional quality articles, addressing advances in fundamental chemistry and interdisciplinary research.